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Abstract Patients with end-stage kidney disease, whether
or not on renal replacement therapy, have an impaired
immune system. This is clinically manifested by a large
percentage of patients unresponsive to the standard vacci-
nation procedure for hepatitis B virus (HBV). In this study,
the immune response to HBV vaccination is related to the
in vitro function of monocyte-derived dendritic cells
(moDC). We demonstrate that mature moDC from non-
responders to HBV vaccination have a less mature pheno-
type, compared to responders and healthy volunteers,
although this did not affect their allostimulatory capacity.
However, proliferation of autologous T cells in the pres-
ence of tetanus toxoid and candida antigen was decreased
in non-responders. Also, HLA-matched CD4+ hsp65-spe-
cific human T-cell clones showed markedly decreased pro-
liferation in the group of non-responders. Our results indi-
cate that impairment of moDC to stimulate antigen-specif-
ic T cells provides an explanation for the clinical immun-
odeficiency of patients with end-stage kidney disease.
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Introduction
Patients with chronic kidney disease (CKD) have an
impaired immune system, which is most evident in
patients with CKD class IV and V (glomerular filtration
rate <30 ml/min) [1]. Clinically, this manifests itself by an
increased susceptibility to infections [2], decreased
delayed-type hypersensitivity responses [3] and an
increased risk of virus-related cancer [4]. In addition, the
immune response to antigens such as tetanus toxoid [5],
diphtheria [6] and hepatitis B surface antigen (HBsAg) [7]
is decreased in patients with CKD.
The immune response to hepatitis B virus (HBV) vac-
cination in patients with CKD shows an inverse relation
with renal function [8]. Despite an intensified vaccination,
up to 40% of the patients undergoing chronic intermittent
haemodialysis (CIHD) do not achieve protective levels of
antibody and are considered to be vaccine non-responders
[9]. In addition, the peak antibody titres are lower [9], and
the antibody titres tend to decrease more rapidly in most of
the patients on CIHD, compared to healthy controls [10].
The mechanism underlying the phenomenon of CKD-
associated hepatitis B immune non-responsiveness is
largely unknown, but the role for dendritic cells (DC) may
be pivotal. DC have a central role in the induction and reg-
ulation of immunity against various antigens [11]. The
function of DC is regulated by a process of differentiation
and their life cycle includes several stages characterised by
distinct functions [12]. Immature DC take up antigen and
process it into peptides that are presented on the cell sur-
face as HLA class II peptide complexes. Immature DC
undergo a process of terminal differentiation which can be
initiated by various stimuli e.g., pro-inflammatory
cytokines, products of microbial pathogens or ligation of
CD40 [12]. Mature DC activate naive and antigen-specif-
ic T helper cells [13] that are able to support the differen-
tiation of B cells into antibody-secreting plasma cells and
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Rotterdam, The Netherlandsmemory B cells. Also, there is evidence that B cells may
differentiate into plasma cells without the interference of T
helper cells but in the presence of DC only [14, 15].
A model of monocyte-derived dendritic cells (moDC)
can mimic the terminal differentiation process from imma-
ture into mature DC, and is used to study DC in vitro [16].
Recently, we have shown that moDC derived from patients
with CKD class IV–V, as well as patients on CIHD, have
a defective terminal differentiation [17]. In the present
study we have related the phenotype and various functions
of moDC from patients on CIHD to their antibody
response after hepatitis B vaccination. Our results reveal
that dysfunction of DC may contribute to the diminished
immune response to T-cell-dependent antigens among
patients with CKD receiving renal replacement therapy.
Patients, materials, and methods
Subjects
All patients had undergone a hepatitis B vaccination procedure,
which consists of 4 intra-muscular injections with 40 μg of
hepatitis B vaccine (HB-VAX, APMSD) at 0, 1, 6 and 12
months. If the antibody response was below 10 IU/ml, the
patients received two additional boosters. Patients were consid-
ered to be non-responders if the antibody response was below 10
IU/ml after six vaccinations. Responders are defined as patients
with an antibody response above 10 IU/ml after 4 vaccinations
(median response 200 IU/ml). All healthy volunteers were vac-
cinated by standard regime of 3 vaccinations whereafter their
antibody titre was at least 1000 IU/ml. No patient was suffering
from a malignancy or autoimmune disease, or was taking
immunosuppressive medication. We included ten non-respon-
ders, ten responders and eight healthy volunteers. Patients were
recruited from a single centre haemodialysis unit at our univer-
sity hospital. The non-responders were recruited prospectively
within a period of two years, with subsequent selection of age-
and sex-matched responders. The clinical characteristics of the
patients included in the study are shown in Table 1. Besides
CKD, diabetes mellitus and age also influence the immune
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response to HBV vaccination [8]. As shown in Table 1, respon-
ders and non-responders did not differ in age and the number of
patients with diabetes mellitus was similar in both groups of
patients. Patients were dialysed three times weekly for 4 h and
water for dialysis was prepared by the use of reverse osmosis
according to European guidelines. The bacteriological quality of
the dialysate was measured at regular intervals according to
European guidelines (endotoxin levels <0.25 IU/ml and <100
colony forming units/ml). All patients were dialysed with
haemophane (MA-12H) (Kawasumi Laboratory Inc., Tokyo,
Japan) dialyser membranes, and received recombinant erythro-
poeitin in a dosage to maintain haemoglobin levels ≥7.0 mmol/l,
and were all treated with 1α,25-dihydroxy vitamin D3. All
patients included gave informed consent and the local medical
ethical committee approved the study.
Isolation and culture of cells
Peripheral blood mononuclear cells (PBMC) were isolated from
50 ml venous blood by Ficoll-Paque plus (Amersham
Biosciences AB, Uppsala, Sweden) density gradient centrifuga-
tion. Monocytes were isolated by positive selection using an
automatic magnetic cell sorter (Miltenyi Biotec, Bergisch
Gladbach, Germany) in combination with CD14 coupled mag-
netic beads (10 μl beads for maximal 60x106 PBMC) (Miltenyi
Biotec). CD14 positive fraction (purity always >95%) was plat-
ed in 6-well plates (Costar, Cambridge, MA) in a density of
1.5x106 cells per well and cultured for 11 days at 37°C in humid-
ified 5% CO2. As culture medium we used RPMI 1640
(Cambrex, Verviers, Belgium) supplemented with 100 IU/ml
penicillin (Cambrex), 100 μg/ml streptomycin (Cambrex), L-glu-
tamin (Cambrex) at 2 mM final concentration and 10% heat-inac-
tivated AB+ pooled human serum. For the cultivation procedure,
50 ng/ml recombinant human GM-CSF (Leucomax, Sandoz,
Germany) and 40 ng/ml recombinant human IL-4 (Tebu-bio,
Heerhugowaard, The Netherlands) were used. Fresh medium and
cytokines were added at days 3, 6 and 8. During the last 3 days
of culture a cytokine cocktail containing IL-1β (10 ng/ml), IL-6
(10 ng/ml), TNFα (20 ng/ml) (Tebu-bio) and PGE2 (1 μg/ml)
(Sigma-Aldrich, Zwijndrecht, The Netherlands) was added as a
maturation stimulus. Viability of all cells was determined by
Trypan blue exclusion.
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Table 1 Clinical characteristics of haemodialysis patients
Responders (n=10) Non-responders (n=10)
Age in years (median and range) 64 (35–81) 66 (44–78)
Male/female ratio 6/4 6/4
Dose of haemodialysis/week 12 h 12 h
Patients with diabetes mellitus 5 4
Underlying kidney disease
Primary kidney disease 2 4
Hypertensive nephropathy 4 3
Diabetic nephropathy 3 2
Other causes 1 1
Haemoglobulin concentration 6.9 mmol/l (range 5.6–8.1) 7.0 mmol/l (range 5.0–8.3)
Plasma albumin concentration 40 g/l (range 36–42) 37 g/l (range 32–42)Immunofluorescence staining and flow cytometric analysis
Antibodies used for cell surface staining included CD86, anti-
HLA-ABC (Serotec, Oxford, UK), CD83 (Pharmingen, San Diego,
USA), anti-HLA-DR (Becton Dickinson, San Jose, USA) and anti-
CCR7 (R&D, Minneapolis, USA). All antibodies were mouse mon-
oclonal antibodies conjugated to either fluorescein isothiocyanate
(FITC) or phycoerythrin (PE). Appropriate isotype controls were
used at the same protein concentration as the test antibody. Data
acquisition and analysis was performed on a FACSCalibur (Becton-
Dickinson) using CellQuest Pro software (Becton-Dickinson).
Results are expressed as mean fluorescence intensity (MFI).
FITC-labelled albumin internalisation
FITC-labelled bovine serum albumin (50 μg/ml) (Sigma-
Aldrich) was added to 1x105 moDC at 37°C. Uptake of the same
concentration of FITC-labelled albumin at 0°C served as nega-
tive control. Both groups were incubated for 60 min in the dark.
After incubation, cells were washed twice in ice-cold Facsflow
(Becton Dickinson) and analysed by FACSCalibur (Becton
Dickinson). Data represent the differences in geometric mean of
moDC after FITC-albumin uptake at 37°C minus 0°C.
Allogeneic mixed leukocyte reaction
The stimulatory capacity of moDC was assessed in an allogeneic
mixed leukocyte reaction (alloMLR). For all assays, CD14 nega-
tive fractions from the same healthy donor were used as respon-
der cells. After isolating monocytes by positive selection using
autoMACS, the negative fraction was resuspended in RPMI 1640
containing 10% heat-inactivated human serum and 10% dimethyl
sulphoxide (Sigma-Aldrich). Aliquots were stored at –80°C for 14
days. Responder cells were thawed immediately before use,
washed and resuspended in RPMI 1640 containing 10% human
serum and plated 5x104 cells per well. Decreasing numbers of
moDC were mixed with the responder cells. As control for back-
ground proliferation, responder cells were cultured in the absence
of moDC. As a positive control for T-cell proliferation, responder
cells were stimulated with phytohaemagglutinin (PHA; 2 μg/ml of
purified PHA-HA16; Murex Biotech Ltd. Kent, England) or phor-
bol myristate acetate (PMA; 100 ng/ml; Calbiochem, Darmstadt,
Germany) and ionomycine (10 μg/ml; Calbiochem). Cells in trip-
licate wells of a 96-well round bottom plate (Nunc, Roskilde,
Denmark) were cultured for 6 days and proliferation was mea-
sured by incorporation of 3H-thymidine (0.5 μCi/well, Amerham
Pharmacia, Biotech, Little Chalfont, UK) for the last 8 h of cul-
ture. The 3H-thymidine incorporation into DNA was assessed by
a liquid scintillation spectrophotometer (Betaplate 1205; LKB
Wallac) and expressed in counts per minute (cpm).
Recall antigen assay
Tetanus toxoid (SVM, Bilthoven, the Netherlands) or Candida
albicans antigen (ARTU, Biological N.V., Lelystad, the
Netherlands) was used to test for recall antigen-specific T-cell
responses. Antigen was added in a final concentration of 35 limit
of flocculation units (Lf)/ml for tetanus toxoid, and 5 μg/ml for
Candida albicans. T cells were prepared using the autologous
CD14 negative fraction and were plated at 1x105 cells per well
with 2x103 moDC. As control for background proliferation,
responder cells were cultured in the absence of moDC and in the
presence of antigen. Cells in triplicate wells of a 96-well round
bottom plate (Nunc) were cultured for 5 days and subsequently
pulsed with 1 μCi 3H-thymidine for the last 8 h of culture. 3H-
thymidine incorporation was measured using a liquid scintilla-
tion counter. Data were expressed in cpm.
CD4+ hsp65-specific T-cell assay
The Mycobacterium tuberculosis and M. leprae hsp65-specific,
HLA-DR3 and HLA-DR1 restricted CD4+ T-cell clones used in
this study recognise an hsp65 determinant, corresponding to pep-
tide residues 3–13 (p3–13) or 411–425 (p411–425), respectively
[18, 19] (both kindly provided by Dr. T.H. Ottenhof and Dr. K.E.
van Meijgaarden, Leiden, the Netherlands). HLA-DR-matched
immature moDC were mixed with 10 μg/ml of appropriate pep-
tides or with 10 μg/ml protein (hsp65). Hsp65-specific T cells
(104) were cultured with different numbers of immature moDC in
96-well round bottom plates (Costar) in triplicates for 3 days.
Likewise, monocytes were tested for their capability to stimulate
hsp65-specific T cells. 3H-thymidine incorporation was measured
on day 4 after a 16-h pulse. For background proliferation, moDC
were cultured in the presence of T cells but in the absence of anti-
gen. As a positive control for T-cell proliferation, responder cells
were stimulated with PHA (2 μg/ml of purified PHA-HA16;
Murex Biotech Ltd.).
Statistical analysis
For moDC, the MFI (phenotype and FITC-labelled albumin
uptake) was logarithmic transformed, and differences between
groups were compared by Student’s two-tailed unpaired t-test,
assuming equal variances. Data obtained from T-cell prolifera-
tion assays were analysed by two-tailed unpaired Mann-Whitney
U-test. These data are expressed as mean±standard error of the
mean, and for FITC-labelled albumin uptake assay data were
expressed as geometric mean±standard deviation. For all assays,
P-value <0.05 was considered significant. Statistical analysis
was performed using GraphPad Prism version 4.00 for Windows
(GraphPad Software, San Diego, CA, USA).
Results
Changes in cell surface markers in response to cytokines
Monocytes from controls, responders and non-responders
were differentiated to similar immature moDC with
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appearances (data not shown). We then provided a
cytokine cocktail that drives all immature moDC into
CD83-positive mature moDC and analysed the phenotype
of mature moDC from the 3 groups. The expression of
DC-related cell surface molecules was significantly lower
on mature moDC from both responders and non-respon-
ders compared to healthy controls (Fig. 1). This is in line
with our previous results [16]. However, there was a grad-
ed decrease in cell surface expression of MHC molecules
class I and II, and CD83 from healthy controls to non-
responders. The cell surface expression of MHC class II
and CD83 was significantly lower in non-responders com-
pared to responders (P<0.05).
FITC-labelled albumin uptake
The uptake of albumin occurs via macropinocytosis [20].
If immature moDC differentiate into mature moDC, they
lose their ability to take up antigen. Therefore determina-
tion of albumin uptake is used to monitor terminal differ-
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entiation [20, 21]. Immature moDC from all three groups
were equally capable of taking up albumin. Mature moDC
from controls showed the lowest uptake of FITC-labelled
albumin compared to moDC from patients. Internalisation
of FITC-albumin was similar between the two groups of
patients (Fig. 2).
Stimulatory properties of MoDC in T-cell proliferation
tests
The mature moDC were highly stimulatory for allogeneic
T cells, even at moDC to T cell ratios of 1:300. However,
no differences were observed in the allostimulatory capac-
ity of moDC between non-uraemic controls, responders
and non-responders (data not shown).
The stimulatory capacity of moDC for antigen-specific
T cells was studied using the recall antigens tetanus toxoid
and candida albicans antigen. Both responders and non-
responders showed less antigen-specific T-cell prolifera-
tion compared to healthy controls. The proliferation of
autologous T cells in the presence of tetanus toxoid and
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Fig. 1 Low expression of CD83, CD86, HLA
class I and II, and chemokine receptor CCR7 on
mature moDC from non-responders and respon-
ders to hepatitis B vaccination. Responders
(n=10) and non-responders (n=10) compared to
healthy controls (n=8). Expression of cell sur-
face antigens is represented as MFI on the Y-
axes. P<0.05 is considered significant and
depicted as ↔candida antigen was most impaired by moDC from non-
responders (Fig. 3). PHA- and PMA-induced proliferation
(the positive control for T-cell proliferation) was similar
between the different groups (data not shown).
CD4+ HSP65-specific T-cell assay
A difference in T-cell composition/function between both
groups of patients may exist, thereby influencing the
results of the recall antigen assay. Therefore, moDC from
patients were used as antigen-presenting cells for HLA-
DR-matched CD4+ antigen-specific human T-cell clones.
In agreement with the recall assays, the proliferation of
CD4+ antigen-specific T cells was markedly decreased in
patients who did not respond to hepatitis B vaccination
(Fig. 4, P=0.05). There was no difference in the prolifera-
tion of CD4+ antigen-specific T cells in response to the
peptide or whole protein (Fig. 4). Compared to monocytes,
immature moDC had a 100-fold higher stimulatory capac-
ity for CD4+ antigen-specific T cells (data not shown).
Discussion
Patients with renal failure are generally poor responders to
vaccination with various antigens including HbSag. Even
in patients responding to vaccination, the antibody titre is
lowered compared to age-matched healthy individuals.
Dysfunctional DC may underlie this impaired immune
response [17]. In this study we tested the hypothesis that
functional impairment of moDC is also related to the
responsiveness to hepatitis B vaccination within the group
of patients with renal failure. Our results indicate that
moDC, from patients on CIHD who showed the most inad-
equate immune response (non-responders to hepatitis B
vaccination), are phenotypically also the most immature
and have a poor stimulatory capacity for memory T cells.
Recently, we showed that moDC from patients with
CKD stage IV and V, with or without haemodialysis, have
a similar differentiation to immature moDC as healthy
controls [17]. However, upon stimulation with diverse
maturation stimuli, like a cocktail of pro-inflammatory
cytokines and CD40 ligand, moDC from patients showed
an impaired terminal differentiation and functionality.
In this study these results were confirmed, as mature
moDC from CIHD patients, compared to healthy controls,
showed less terminal differentiation as judged by the
expression of cell surface molecules studied. However, the
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Fig. 2 No difference between moDC from responder and non-
responders in uptake of FITC-labelled albumin. Uptake of FITC-
labeled albumin by immature and cytokine-induced mature moDC
derived from controls (n=8), non-responders (n=9) and responders
(n=9). Endocytosis was measured by flowcytometry, and is denot-
ed as geometric mean of the fluorescents intensity±SD. *P<0.05 is
considered significant by unpaired Student’s t-test
Fig. 3 Immature moDC from non-responders have an impaired
ability to induce autologous T-cell proliferation in the presence of
recall antigens. Proliferative response of autologous T cells to
moDC and the recall antigens tetanus toxoid and Candida albi-
cans. Data are analysed by Mann–Whitney U-test and are
expressed in counts per minute (cpm)±SEM. P<0.05 is considered
significant
Fig. 4 Immature moDC from non-responders have an impaired
ability to induce T-cell proliferation in the presence of recall anti-
gens. To exclude autologous T-cell anomalies as a cause for dimin-
ished T-cell responses upon recall antigens, autologous T cells
were replaced by an HLA-matched hsp65-specific T-cell clone.
Patients that were included have been immunophenotyped DR1 or
DR3 (non-responders n=4; responders n=3). P=0.05 and is depict-
ed as *moDC from non-responders showed the most profound
decrease in the expression of these cell surface molecules,
noticeably the HLA molecules and CD83. This was not
reflected by a lowered stimulatory capacity for allogeneic
T cells, but evidently present when the moDC from non-
responders were tested as antigen-presenting cells for
memory T cells. This held true, not only for autologous
tetanus toxoid and candida albicans antigen-specific T
cells, but also for an HLA-matched hsp65 antigen-specific
T-cell line.
Besides the expression of MHC and co-stimulatory
molecules, the T-cell stimulatory capacity of moDC is
influenced by their cytokine production and their ability to
take up and process antigen effectively. We already docu-
mented that mature moDC from patients on CIHD do not
differ from healthy controls with respect to their Th1 and
Th2 polarisation capacity, or cytokine production like IL-
10, IL-12p70 and IL-15 [17]. The results obtained in this
study do not indicate a difference in antigen uptake and
processing. For instance, the uptake of FITC-labelled
albumin was similar between responders and non-respon-
ders. In addition, a difference in antigen processing seems
unlikely because the moDC loaded with total protein
induced a similar proliferative response of the hsp-65-spe-
cific T cells as compared to moDC loaded with peptide
only. Therefore, the decreased stimulatory capacity of
moDC from patients on CIHD, and more specifically non-
responders, seems to be related to the decreased expres-
sion of molecules necessary for T-cell stimulation.
There is a paucity of data on the function of antigen
presentation in patients with CKD, but our results are
remarkably consistent with the conclusions of previous
studies. Meuer et al. found a correlation between a
decreased T-cell proliferation response in vitro and a low
or no antibody response in vivo [22]. This response could
be restored to normal using healthy donor-derived mono-
cytes as antigen-presenting cells. Similar results were
found for tetanus toxoid-specific T-cell responses in
patients on CIHD [23]. It should be emphasised that these
studies used monocyte populations contaminated with DC
and that the precise contribution of either cell type is
therefore not defined. Even minor contamination of DC
may influence results substantially because the DC are
many times more potent as antigen-presenting cell than
monocytes. In our hands, highly purified monocytes have
little or no capacity for antigen presentation to allogeneic
T cells and autologous memory T cells (this study and
[24]). Therefore, the results obtained in previous studies
may in fact be related to a difference in function of DC. In
addition, we observed a strong negative correlation
between the number of peripheral blood DC and the stage
of CKD [25]. Therefore, loss of renal function not only
negatively affects the in vitro maturation of monocytes to
DC, as is shown in this study, but also the presence of cir-
culating DC in vivo.
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At present it is not clear which factors underlie the
impaired terminal differentiation of moDC. One must
assume that the difference is already present at the level of
monocytes as these are the starting population of cells,
which are cultured under identical circumstances for both
patients and healthy controls. A number of studies have
pointed out an activated status of monocytes derived from
patients on CIHD compared to healthy controls.
Furthermore, a high production of TNF-α and IL-6 by
LPS-stimulated monocytes was shown, which probably
represents significant pre-activation of these cells, corre-
lated with the unresponsiveness to HBV vaccination
among dialysis patients [26]. Therefore, one may hypoth-
esise that pre-activation of monocytes impairs the full mat-
uration into DC, but data to support this concept are as yet
not available.
In conclusion, DC of patients on CIHD show an
impaired terminal differentiation and relative dysfunction
as antigen-presenting cells for memory T cells. This is
most evident in patients that are not able to mount a suffi-
cient antibody response after HBV vaccination.
Dysfunction of DC may therefore lie at the heart of the
disturbed immune system of patients with CKD.
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